Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    October 2021
  1. CHENG L, Zhang D, Yan W
    Ultrasoundtargeted microbubble destructionmediated overexpression of Sirtuin 3 inhibits the progression of ovarian cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  2. LI H, Liu Y, Wang Y, Zhao X, et al
    Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    September 2021
  3. PAN Y, Zhang L, Zhang X, Liu R, et al
    [Retracted] Synergistic effects of eukaryotic coexpression plasmidbased STAT3specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    August 2021
  4. WEN J, Han S, Cui M, Wang Y, et al
    [Retracted] Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    June 2021
  5. CUI S, Li C
    RHPN1AS1 promotes ovarian carcinogenesis by sponging miR4855p and releasing TPX2 mRNA.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    May 2021
  6. ZHONG Y, Le F, Cheng J, Luo C, et al
    Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatinresistant SKOV3/DDP ovarian cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  7. LIANG X, Ju J
    Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  8. LI M, Zhang S, Ma Y, Yang Y, et al
    Role of hsamiR105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  9. FREUND E, Miebach L, Stope MB, Bekeschus S, et al
    Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    April 2021
  10. CAO S, Chen C, Xue J, Huang Y, et al
    [Corrigendum] Silencing of type Igamma phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available


  11. LEE SY, Kwon J, Lee KA
    Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  12. CHEN J, Chen H, Pan L
    SIRT1 and gynecological malignancies (Review).
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    December 2020
  13. WEI L, He Y, Bi S, Li X, et al
    miRNA199b3p suppresses growth and progression of ovarian cancer via the CHK1/Ecadherin/EMT signaling pathway by targeting ZEB1.
    Oncol Rep. 2020 Dec 11. doi: 10.3892/or.2020.7895.
    PubMed     Abstract available


  14. AN Q, Liu T, Wang MY, Yang YJ, et al
    KRT7 promotes epithelialmesenchymal transition in ovarian cancer via the TGFbeta/Smad2/3 signaling pathway.
    Oncol Rep. 2020 Dec 8. doi: 10.3892/or.2020.7886.
    PubMed     Abstract available


  15. ZHAO L, Liu Z, Deng X, Wang J, et al
    Polyphyllin VII induces mitochondrial apoptosis by regulating the PP2A/AKT/DRP1 signaling axis in human ovarian cancer.
    Oncol Rep. 2020 Dec 2. doi: 10.3892/or.2020.7879.
    PubMed     Abstract available


  16. BRUM MCM, Dos Santos Guimaraes I, Ferreira LB, Rangel LBA, et al
    Osteopontinc isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
    Oncol Rep. 2020 Dec 1. doi: 10.3892/or.2020.7877.
    PubMed     Abstract available


    November 2020
  17. LEE DW, Lee W, Kwon M, Lee HN, et al
    Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
    Oncol Rep. 2020 Nov 11. doi: 10.3892/or.2020.7845.
    PubMed     Abstract available


  18. ZHAO M, Ji H, Fu Q, Cheng Q, et al
    MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro.
    Oncol Rep. 2020 Nov 10. doi: 10.3892/or.2020.7844.
    PubMed     Abstract available


    October 2020
  19. ZHANG H, Hu L, Cheng M, Wang Q, et al
    The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Oncol Rep. 2020 Oct 9. doi: 10.3892/or.2020.7798.
    PubMed     Abstract available


    September 2020
  20. LIU P, Zhong Y, Cao T, Sheng X, et al
    A frequent somatic mutation in the 3'UTR of GAPDH facilitates the development of ovarian cancer by creating a miR125b binding site.
    Oncol Rep. 2020;44:887-896.
    PubMed     Abstract available


  21. ZHOU S, Wang R, Xiao H
    Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
    Oncol Rep. 2020;44:927-938.
    PubMed     Abstract available


  22. ZHANG R, Chen X, Fu S, Xu L, et al
    A small molecule STAT3 inhibitor, LLL12, enhances cisplatin and paclitaxelmediated inhibition of cell growth and migration in human ovarian cancer cells.
    Oncol Rep. 2020;44:1224-1232.
    PubMed     Abstract available


    July 2020
  23. WEN J, Han S, Cui M, Wang Y, et al
    Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis.
    Oncol Rep. 2020 Jul 17. doi: 10.3892/or.2020.7694.
    PubMed     Abstract available


    May 2020
  24. PEI Y, Li K, Lou X, Wu Y, et al
    miR1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.
    Oncol Rep. 2020 May 25. doi: 10.3892/or.2020.7623.
    PubMed     Abstract available


    March 2020
  25. QIN J, Fu M, Wang J, Huang F, et al
    PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin3gallate in ovarian cancer.
    Oncol Rep. 2020 Mar 31. doi: 10.3892/or.2020.7571.
    PubMed     Abstract available


  26. WANG L, Li X
    Identification of an energy metabolismrelated gene signature in ovarian cancer prognosis.
    Oncol Rep. 2020 Mar 17. doi: 10.3892/or.2020.7548.
    PubMed     Abstract available


    February 2020
  27. SHEN JJ, Zhu XF, Xu J, Wang ZF, et al
    Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARgammadependent reversal of the progesterone receptor membrane component 1/2 expression profile.
    Oncol Rep. 2020 Feb 21. doi: 10.3892/or.2020.7509.
    PubMed     Abstract available


    December 2019
  28. LIU CL, Pan HW, Torng PL, Fan MH, et al
    SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.
    Oncol Rep. 2019;42:2706-2715.
    PubMed     Abstract available


    November 2019
  29. GAO S, Bian T, Su M, Liu Y, et al
    miR26a inhibits ovarian cancer cell proliferation, migration and invasion by targeting TCF12.
    Oncol Rep. 2019 Nov 26. doi: 10.3892/or.2019.7417.
    PubMed     Abstract available


    October 2019
  30. DONG J, Xu M
    [Corrigendum] A 19miRNA Support Vector Machine classifier and a 6miRNA risk score system designed for ovarian cancer patients.
    Oncol Rep. 2019 Oct 23. doi: 10.3892/or.2019.7385.
    PubMed     Abstract available


  31. WEI X, Jia Y, Lou H, Ma J, et al
    Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway.
    Oncol Rep. 2019 Oct 14. doi: 10.3892/or.2019.7370.
    PubMed     Abstract available


  32. SUN D, Liu J, Zhou L
    Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR646/VAMP2 and miR647/MDM2 signaling pathways.
    Oncol Rep. 2019 Oct 10. doi: 10.3892/or.2019.7366.
    PubMed     Abstract available


    September 2019
  33. ISHIKURA N, Yorozu K, Kurasawa M, Yanagisawa M, et al
    Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Oncol Rep. 2019;42:1057-1065.
    PubMed     Abstract available


    August 2019
  34. VACLAVIKOVA R, Klajic J, Brynychova V, Elsnerova K, et al
    Development of highresolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
    Oncol Rep. 2019;42:763-774.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: